Clinical Trial

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Study acronym: MRD
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2022-01-25; most recent amendment 2026-01-08.
Status change: Recruiting → Active, Not Recruiting 2025-05-30
Trial Details
NCT Number NCT05210283
Lead Sponsor Exact Sciences Corporation
Collaborators: NSABP Foundation Inc
Conditions Colorectal Cancer
Enrollment 1,017 participants
Start Date 2021-12-15
Primary Completion 2027-05-15 (estimated)
Study Completion 2027-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-12